Valneva Capitalizes on FDA Priority Review Voucher, Fuels Further Vaccine Development

Valneva Sells Priority Review Voucher for $103 Million

French vaccine maker Valneva has sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million. This significant transaction not only represents a substantial financial gain for Valneva but also underscores the value of FDA priority review vouchers in the pharmaceutical industry. The sale of the PRV may also point to Valneva's strategic focus on its core vaccine development activities.

Priority Review Voucher: A Reward for Tropical Disease Vaccine

Valneva was awarded a tropical disease PRV in November 2023 following U.S. FDA approval of IXCHIQ, the company's single dose live attenuated vaccine. This vaccine is indicated for the prevention of disease caused by the chikungunya virus (CHIKV) in individuals 18 years of age and older who are at an increased risk of exposure to CHIKV.

Investing in Future Vaccine Development

Valneva intends to invest the proceeds from the sale of the PRV into its research and development projects. This includes the co-development of its Phase 3 vaccine candidate against Lyme disease and additional clinical trials for its chikungunya vaccine IXCHIQ. The funds will also be used for the expansion of the company's clinical pipeline. This strategic reinvestment signifies Valneva's strong commitment to continue addressing unmet medical needs through the development of innovative vaccines.

Global Market Demand for Chikungunya Vaccine

Chikungunya, a mosquito-borne viral disease, has a high global market demand for vaccines. The market is estimated to exceed $500 million annually by 2032. Valneva's IXCHIQ represents the world's first and only chikungunya vaccine. It is a live attenuated vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 18 years of age and older.

Valneva: A Leader in Vaccine Development

Specializing in the development, manufacture, and commercialization of prophylactic vaccines for infectious diseases, Valneva SE has a strong track record in the industry. Currently, the company markets three proprietary travel vaccines, including the world's first and only chikungunya vaccine. The sale of the PRV and the planned reinvestment of the proceeds underlines Valneva's commitment to continue delivering innovative solutions to address unmet medical needs worldwide.